Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rectal Abberant Crypt Foci And Other Intermediate Biomarkers For Sporadic Colorectal Neoplasia: Cross-Sectional Prevelance And Modulation By Celecoxib

NCT00043043 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00043043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00043043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rectal Abberant Crypt Foci And Other Intermediate Biomarkers For Sporadic Colorectal Neoplasia: Cross-Sectional Prevelance And Modulation By Celecoxib
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2003
Completion date
October 31, 2007
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer